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INTRODUCTION
Here, we report on PID1 (Phosphotyrosine interaction domain containing 1) in two important groups of brain tumors: embryonal brain tumors (medulloblastomas and atypical teratoid rhabdoid tumors (ATRT)) and gliomas. Medulloblastomas are the most common malignant brain tumors in children, where in high-risk disease prognosis remains poor. Moreover, in younger children, therapies that include whole brain irradiation are associated with serious long-term sequelae that hamper quality of life of survivors (1, 2) . ATRT is another poor-prognosis, highly malignant embryonal brain cancer of young children. Most ATRTs have lost expression and/or function of the INI1 (SMARCB1) tumor suppressor gene, which is part of the SWI/SNF chromatin-remodeling complex (3) (4) (5) . Malignant gliomas, including glioblastoma multiforme (GBM), comprise the most common primary malignant brain tumors in adults and also carry poor prognosis (6, 7) . Here, we provide novel clinical correlations of PID1 in medulloblastomas and gliomas, and demonstrate tumor-inhibitory effects of PID1 in cell lines of these three brain tumors.
The PID1 gene (also called NYGGF4 and PTB-containing, cubilin and LRP1-interacting protein; PCLI1; rhymes with "BID-1") was identified in 2006 based on its differential expression in adipose tissue of obese compared to non-obese subjects (8) . To date, PID1 has not been reported in the context of cancer. While PID1 is known to contain a phosphotyrosine binding (PTB) domain/phosphotyrosine interaction domain (PID) (8) , the molecular mechanism(s) underlying its activities are poorly understood. PID1 mRNA increases during differentiation of 3T3-L1 pre-adipocytes to adipocytes (8) , and is lower in brains of Alzheimer patients compared to controls (9) . PID1 overexpression increases proliferation of 3T3-L1 pre-adipocytes, but does not alter their adipogenic differentiation (8) . In NIH-3T3 cells, however, overexpression of PID1 Erdreich-Epstein et al 5 amino acids 84-230, which includes its PTB domain, causes cell cycle arrest (10) , suggesting that PID1 function may differ depending on cellular context. Pilot microarray expression analysis identifying PID1 mRNA level as highly correlated with outcome in medulloblastomas. A similar correlation of PID1 mRNA levels in gliomas using publicly-available microarray datasets prompted us to study PID1 in more detail. Analysis revealed highly significant correlations between PID1 mRNA and survival and between PID1 mRNA and subgroup and/or grade in medulloblastomas and gliomas across six independent datasets. Moreover, ectopic expression of PID1 in embryonal brain tumor cell lines (medulloblastomas and ATRT) and GBM cell lines showed consistent growth-inhibitory effects.
These data are the first to link PID1 to cancer in general and to brain tumors in particular, and to suggest that PID1 may have a growth-inhibitory function in medulloblastomas, glioblastomas and ATRT.
Research. medulloblastomas, profiled on Affymetrix U133 plus2.0 arrays, and is a combination of published data on 230 patients obtained from the Gene Expression Omnibus (GSE10327, GSE12992, and GSE37418) (11) (12) (13) and unpublished data on 216 additional patients from Heidelberg (Kool and Pfister, unpublished data). The published Toronto microarray dataset includes 103 medulloblastomas profiled on Affymetrix Human Exon Array data (GSE21140), and the published Boston microarray dataset includes 194 medulloblastomas profiled on Affymetrix U133A (14, 15) . Molecular subgroups of medulloblastoma were identified either by using available published data, or by cluster analyses to assign molecular subgroup for the unpublished datasets (11, 12, 14) , or for the CHLA analysis, by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and a medulloblastoma gene signature derived from prior microarray studies (15, 16) and a CHLA study (manuscript in preparation).
Glioma PID1 mRNA microarray data in REMBRANDT (REpository for Molecular BRAin Neoplasia DaTa) were analyzed using Affymetrix U133 plus2.0 arrays (17) . Glioblastoma PID1 mRNA data in TCGA (The Cancer Genome Atlas; The Cancer Genome Atlas Research Network, National Cancer Institute and National Human Genome Research Institute, Bethesda, MD, USA) were analyzed using AgilentG4502A_07) (18) . For GBM clinical and PID1 correlations, publicly available data for 196 patients was obtained from TCGA and Verhaak et al (19) , and was accessed at https://tcga-data.nci.nih.gov/docs/publications/gbm_exp/ (files:
Research. RNA from CHLA medulloblastoma samples was extracted and processed using a previously published method (20) . PID1 mRNA levels were obtained by qRT-PCR (PID1: Forward Primer:
5'-GATTGCTGGCAACCACCTGATGT-3', reverse primer: 5'-AAATGTAAAGGTTGGCAGGGC CAC-3', probe: 5'-TCGAGGACATGTTCTTCTCCAGACGT-3') and after normalization to three housekeeping genes (GAPDH/SDHA/HPRT1). 
Cell Culture
The cell lines used were: GBM (U87, U251, LN18, LN229, CHLA-07-DIPG), medulloblastoma 
Statistical Analysis
Details of the statistical analysis of patient-related information can be found in the Supplemental
Materials.
In vitro experiments were analyzed using GraphPad Prism version 5.0 for MAC (GraphPad Software, San Diego California USA, www.graphpad.com). Results are depicted as mean±SEM from at least three independent experiments unless stated otherwise. P-values represent unpaired two-sided Student's t-test unless stated differently. 
RESULTS

PID1 mRNA is higher in favorable medulloblastomas and correlates with longer rf-PFS and OS in medulloblastoma patients.
Quantitative RT-PCR of 81 pediatric medulloblastoma tumors showed that mean PID1 mRNA levels were significantly higher in medulloblastomas with desmoplastic/nodular histology compared to those with anaplastic histology (p<0.001; Fig 1A; patient characteristics in Supplemental Table 1 ). Supporting this, analysis of PID1 in the four medulloblastoma core molecular subgroups (11, 22, 23) showed that SHH group medulloblastomas had higher mean PID1 mRNA compared with the less favorable subgroup, Group 3 and Group 4 ( Fig 1B) .
Microarray data from three other independent medulloblastoma datasets similarly revealed higher mean PID1 mRNA in the more favorable subgroups (SHH and WNT) compared to medulloblastomas in Groups 3 and 4 ( Fig 1C and Supplemental Fig 1A) (11) (12) (13) . Mean expression of PID1 mRNA was higher in fetal cerebellum compared to Groups 3 and 4 medulloblastomas, and was similar to PID1 mRNA in the WNT and SHH groups ( Fig 1C) .
In univariate analysis of the CHLA medulloblastoma patients (n=81, Supplemental Table 1 ), rf-PFS was significantly longer in children whose tumor PID1 mRNA was higher than the median of the cohort, compared to those with tumor PID1 mRNA lower than median (rf-PFS 73%±11% vs. 11%±10%, respectively; p<0.001, Fig 1D) . Difference in rf-PFS also remained significant when dividing the group into equal tertiles according to PID1 mRNA (Suppl Fig 1B) . In the non-CHLA medulloblastoma patients from Fig 1C for whom survival data were available, OS was significantly longer in patients with higher tumor PID1 mRNA compared to those with lower PID1 mRNA (Fig 1E) , supporting the findings in the CHLA cohort ( Fig 1D) . In multivariate analysis of the CHLA cohort, risk of radiation-free disease progression was significantly higher in patients with lower-than-median PID1 mRNA compared to those with higher-than-median PID1 mRNA (Table 1 ). and Group 4), and that higher medulloblastoma PID1 mRNA correlated with longer rf-PFS and OS.
GBM have lower PID1 mRNA compared to other gliomas and non-tumor brains; Higher PID1 mRNA correlates with longer overall survival in glioma patients.
Analysis of PID1 mRNA data using the REMBRANDT glioma clinical genomics database (17) revealed that PID1 mRNA levels were lower in the highest grade gliomas, GBMs, compared to non-tumor brains, astrocytomas and oligodendrogliomas (Fig 2A) . The TCGA glioma dataset (18) similarly showed that mean PID1 mRNA in GBM was significantly lower than its level in non-tumor brains (CI95% 0.34-0.38, p<0.0001; Fig 2B) . For GBM patients for whom tumor molecular subtype (classical, mesenchymal, neural, proneural) and clinical data were available and unified PID1 mRNA expression values from three platforms in TCGA were analyzed (see Methods), there were significant differences in mean PID1 mRNA among the molecular subtypes (p<0.0001; Suppl Fig 2A, Supplemental Table 2 ). Neural and proneural GBM subtypes showed higher PID1 mRNA compared to classical and mesenchymal subtypes. All paired comparisons between GBM with known subtypes were also significantly different (after Bonferroni adjustment for multiple comparisons) with the exception of the Neural vs. Proneural pairing (p=0.88). Differences in PID1 mRNA between GBM subtypes remained significant even after adjusting for age at diagnosis (p<0.0001).
Research. Survival analysis using the REMBRANDT dataset revealed significant differences in OS among patients who were stratified according to PID1 mRNA. PID1 mRNA was directly correlated to OS in patients with any diagnosis of glioma, or within the subset of astrocytomas that does not include GBMs (Fig 2C-D, Suppl Fig 2B-E ; using two available PID1 probesets). For GBMs in the TCGA dataset PID1 mRNA was univariately significantly associated with survival (Cox regression analysis, p=0.031; Fig 2E) , but the REMBRANDT dataset did not reveal such correlation (not shown). While the PID1 mRNA association with OS in GBM (TCGA) was no longer significant after adjusting for molecular subtype (p=0.15), the relative failure rate decrease per unit increase in PID1 mRNA was only slightly attenuated in our analysis (0.83 ± 0.071 univariate, 0.85±0.094 multivariate). In Cox multivariate analysis, with age at diagnosis, and PID1 expression and subtype as variables (TCGA), PID1 was marginally significant (p=0.056). The relative failure rate decrease per unit increase in PID1 mRNA was 0.81 ± 0.091.
Thus, similar to our findings in medulloblastomas, the most malignant gliomas (i.e., GBMs) had lower PID1 mRNA compared to other gliomas or to non-tumor brains. Additionally, higher tumor PID1 mRNA correlated with longer OS in glioma patients.
PID1 confers growth disadvantage in brain tumor cell lines
We next asked if the clinical correlations we found for PID1 mRNA pointed to a possible biological role for PID1 in brain tumors. To evaluate a role in growth, we assessed the effect of PID1 on colony formation in U251 GBM, LN229 GBM, D283MED medulloblastoma, and CHLA- (Fig 3A-B) . Both variants of PID1 (variant 1: NM_017933, variant 2: NM_001100818) showed similar effects in this assay. Similar inhibition of colony formation was also observed using the self-cleaving bicistronic pCLS-PID1-2A-eGFP compared with its control vector, pCLS-2A-eGFP (21) as well as with the bicistronic pCIENS-PID1 compared to pCIENS control vector (Suppl Fig 3A-B) . Expression of PID1 at the time of flow-sorting and plating of the tGFP-expressing cells was verified by western blotting (24 hr after transfection, Suppl Fig 3C) . These data indicate that PID1 confers growth and/or survival disadvantage upon brain tumor cell lines ectopically expressing PID1.
PID1 inhibits proliferation and promotes of cell death of cultured brain tumor cell lines
To characterize the PID1-induced growth disadvantage, we analyzed proliferation and cell (Fig 4A-B and Suppl Fig 4) , indicating that PID1 increased cell death. PID1-tGFP also decreased proliferation, as indicated by the decreased proportion of cells in S-phase ( Figure 4A -B). Apoptosis accounted for at least some of the cell death, as annexinV binding was higher in PID1-tGFP-expressing cells compared to tGFP controls (Fig 4C) . There were very few 7AAD-positive/annexinV-negative cells, indicating that necrosis was only minimal. As mitochondria are involved in metabolism and several forms of cell death and PID1 has been reported to induce mitochondrial dysfunction in adipocytes and myocytes (24-28), we examined the effect of PID1 on mitochondrial depolarization. U251 GBM, D283MED medulloblastoma and CHLA-06-ATRT cell lines transfected with PID1-tGFP showed increased depolarization of mitochondrial membrane potential compared with tGFP-transfected cells 24 hr after transfection (Fig 4D) . Conversely, siRNA knockdown of PID1 in U87 GBM (U87 express PID1 protein; see Suppl Fig   5) , diminished baseline depolarization of the mitochondrial membrane potential compared to non-silencing siRNA control (Fig 4E) . siPID1 knockdown similarly diminished baseline mitochondrial depolarization in D283MED medulloblastoma cells (Fig 4E) . These data demonstrate that the inhibitory effect of PID1 on brain tumor cell line growth is the result of both inhibition of proliferation and increased cell death, and is associated with depolarization of mitochondrial membrane potential.
Last, to begin investigating the molecular mechanism of PID1, we examined its effect on serummediated phosphorylation of AKT and ERK, two effectors which are central to a number of proliferation and survival signaling pathways. LN229 GBM cells transiently transfected with PID1, serum starved overnight and acutely stimulated with 20% FBS showed decrease in the serum-induced phosphorylation of AKT compared with empty vector-transfected cells (Fig 4F) .
Additionally, transient transfection of PID1 into D283MED medulloblastoma cells grown in FBS-
containing medium caused decrease in phosphorylation of both AKT and ERK (Fig 4G and   Suppl Fig 6) . This indicates that PID1 inhibits serum-mediated signaling pathways which involve AKT and ERK.
In summary, using six independent datasets, we have shown that PID1 mRNA is lower in the more aggressive medulloblastomas and gliomas compared to their relatively more favorable counterparts, and that higher PID1 mRNA correlates with longer rf-PFS and OS in medulloblastoma patients and longer OS in glioma and GBM patients. We also showed that PID1 conferred a growth-inhibitory effect on cell lines of three types of brain tumors 
DISCUSSION
The small number of articles reporting on PID1 to date have mostly been in the context of obesity and diabetes in adipocytes and muscle cells (8, (28) (29) (30) and in Alzheimer's brains (9) .
Our work here is the first to report on PID1 in cancer.
Our clinical findings for PID1 using six independent datasets comprising two different types of brain cancers emphasize the validity of the association between lower PID1 mRNA and less favorable tumor subgroups. The in vitro experiments suggest that PID1 confers growth suppression due to combined inhibition of proliferation and increase in cell death. Regulation of PID1 expression in embryonal brain tumors and gliomas is currently unknown.
The molecular mechanism by which PID1 affects growth of brain tumor cells in culture is also unknown at this time. Our finding on depolarization of mitochondrial membrane potential by PID1 in brain tumor cell lines is consistent with reports that PID1 disrupts mitochondrial function in adipocytes and muscle cells (24) (25) (26) (27) (28) . In adipocytes and muscle cells, PID1 also inhibits insulin-mediated phosphorylation of IRS-1 and AKT, and insulin-mediated translocation of the GLUT-4 glucose transporter to the membrane, resulting in decreased glucose uptake (28) (29) (30) .
Our experiments showing that PID1 inhibits phosphorylation of AKT and ERK suggest that PID1 may modulate signaling pathways involved in cell proliferation and survival. While insulin signaling is less likely to be a target of PID1 modulation in brain tumor cell lines due to their low and/or infrequent expression of the insulin receptor, it will be interesting to examine if PID1 modulates signaling through the insulin-like growth factor receptor (IGF1R), which is important 
show growth-inhibitory effect of PID1 in cultured medulloblastoma, GBM and ATRT cell lines.
Our data therefore suggest that PID1 may have a growth-modulating function in brain tumors. It will now be important to further investigate the molecular mechanism(s) of PID1's effects in pediatric and adult malignant brain tumors.
Research. 4 Missing data for these variables were included in the models as a "missing" category. 
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